Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin

Brad Clark, Sarah M. Woolford, Annette Eastwood, Ken Sharpe, Peter G. Barnes, Christopher J Gore

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.

Original languageEnglish
Pages (from-to)1561-1571
Number of pages11
JournalDrug Testing and Analysis
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2017

Fingerprint

hematology
Physiology
Hematology
Erythropoietin
physiology
Athletes
Doping (additives)
Physiological Adaptation
dose
hemoglobin
bycatch
Exercise Test
Sports
Hemoglobins
Blood
blood
Placebos
Control Groups

Cite this

Clark, Brad ; Woolford, Sarah M. ; Eastwood, Annette ; Sharpe, Ken ; Barnes, Peter G. ; Gore, Christopher J. / Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin. In: Drug Testing and Analysis. 2017 ; Vol. 9, No. 10. pp. 1561-1571.
@article{7b200c251c20413383e0e5f1d68d99a1,
title = "Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin",
abstract = "There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.",
keywords = "ABP, EPO, doping, micro-dosing, performance",
author = "Brad Clark and Woolford, {Sarah M.} and Annette Eastwood and Ken Sharpe and Barnes, {Peter G.} and Gore, {Christopher J}",
year = "2017",
month = "10",
doi = "10.1002/dta.2176",
language = "English",
volume = "9",
pages = "1561--1571",
journal = "Drug Testing and Analysis",
issn = "1942-7603",
publisher = "John Wiley & Sons",
number = "10",

}

Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin. / Clark, Brad; Woolford, Sarah M.; Eastwood, Annette; Sharpe, Ken; Barnes, Peter G.; Gore, Christopher J.

In: Drug Testing and Analysis, Vol. 9, No. 10, 10.2017, p. 1561-1571.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin

AU - Clark, Brad

AU - Woolford, Sarah M.

AU - Eastwood, Annette

AU - Sharpe, Ken

AU - Barnes, Peter G.

AU - Gore, Christopher J

PY - 2017/10

Y1 - 2017/10

N2 - There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.

AB - There is evidence to suggest athletes have adopted recombinant human erythropoietin (rHuEPO) dosing regimens that diminish the likelihood of being caught by direct detection techniques. However, the temporal response in physiology, performance, and Athlete Biological Passport (ABP) parameters to such regimens is not clearly understood. Participants were assigned to a high-dose only group (HIGH, n = 8, six rHuEPO doses of 250 IU/kg over two weeks), a combined high micro-dose group (COMB, n = 8, high-dose plus nine rHuEPO micro-doses over a further three weeks), or one of two placebo control groups who received saline in the same pattern as the HIGH (HIGH-PLACEBO, n = 4) or COMB (COMB-PLACEBO, n = 4) groups. Temporal changes in physiology and performance were tracked by graded exercise test (GXT) and haemoglobin mass assessment at baseline, after high dose, after micro-dose (COMB and COMB-PLACEBO only) and after a four-week washout. Venous blood samples were collected throughout the baseline, rHuEPO administration, and washout periods to determine the haematological and ABP response to each dosing regimen. Physiological adaptations induced by a two-week rHuEPO high-dose were maintained by rHuEPO micro-dosing for at least three weeks. However, all participants administered rHuEPO registered at least one suspicious ABP value during the administration or washout periods. These results indicate there is sufficient sensitivity in the ABP to detect use of high rHuEPO doping regimens in athletic populations and they provide important empirical examples for use by anti-doping experts.

KW - ABP

KW - EPO

KW - doping

KW - micro-dosing

KW - performance

UR - http://www.scopus.com/inward/record.url?scp=85017437045&partnerID=8YFLogxK

U2 - 10.1002/dta.2176

DO - 10.1002/dta.2176

M3 - Article

VL - 9

SP - 1561

EP - 1571

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

SN - 1942-7603

IS - 10

ER -